Skip to main content
ADALTA LIMITED logo

ADALTA LIMITED — Investor Relations & Filings

Ticker · 1AD ISIN · AU0000001AD2 LEI · 254900XT3BQIT6GR6M94 ASX Professional, scientific and technical activities
Open in API
Filings indexed 726 across all filing types
Latest filing 2024-04-28 Share Issue/Capital Cha…
Country AU Australia
Listing ASX 1AD

About ADALTA LIMITED

https://adalta.com.au/

AdAlta Limited is a clinical-stage biotechnology company focused on the discovery and development of a new class of protein therapeutics called i-bodies. The company utilizes its proprietary i-body platform to engineer highly stable, small-format proteins that mimic the binding characteristics of shark antibodies. These i-bodies are designed to target complex disease-related proteins that are often inaccessible to traditional monoclonal antibodies. AdAlta's lead therapeutic candidate, AD-214, is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic conditions. The platform's versatility allows for the creation of diverse therapeutic leads across multiple disease areas, including inflammation and oncology, by leveraging the unique structural properties of the human protein scaffold-based i-body library.

Recent filings

Filing Released Lang Actions
Cleansing Notice under Section 708A 1 page 276.8KB
Share Issue/Capital Change Classification · 100% confidence The document is a short announcement (1200 characters) notifying the market of a share issuance under section 708A(5)(e) of the Corporations Act 2001 (Cth). It states the number of shares issued and compliance with relevant legal provisions. There is no financial data, no detailed report, and it is clearly an announcement related to capital changes. According to the definitions, this fits the category of Share Issue/Capital Change (SHA). The document is not a full report but a regulatory announcement about a capital event.
2024-04-28 English
Notification of Expiry of Listed Options 5 pages 722.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an ASX announcement dated 24 April 2024 from AdAlta Limited regarding the notice of listed options and exercise instructions. It details the number of listed options, exercise price, expiry date, and instructions for option holders on how to exercise their options or let them expire. The document includes a formal notice to option holders, payment instructions, and contact information. There is no financial data, earnings information, or report content. Instead, it is an official announcement informing shareholders about the option expiry and exercise process, which relates to capital structure changes. Therefore, this document fits the category of Share Issue/Capital Change (SHA) as it concerns the exercise of listed options and potential issuance of shares upon exercise.
2024-04-23 English
SYNBV MoU Webinar presentation 18 pages 2.8MB
Investor Presentation Classification · 95% confidence The document is an investor webinar presentation dated April 10, 2024, focused on AdAlta Limited's collaboration with SYNBV to develop next generation cellular immunotherapies. It contains detailed strategic information, market analysis, partnership terms, and scientific insights. The content is structured as a presentation with disclaimers, market data, and strategic outlook rather than a formal regulatory filing or financial report. There are no financial statements, audit opinions, voting results, or legal proceedings discussed. The document is clearly intended for investors to inform them about the company's strategy, partnerships, and market opportunity, which aligns with the definition of an Investor Presentation (IP). The length (15,000 characters) and detailed content support this classification rather than a brief announcement or regulatory filing.
2024-04-09 English
SYNThesis BioVentures MoU for cellular immunotherapies 6 pages 239.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 8 April 2024 from AdAlta Limited. It details a Memorandum of Understanding (MoU) with SYNthesis BioVentures to form a special purpose entity for developing next-generation cell-based immunotherapies. The content focuses on the partnership, strategic collaboration, and business development plans rather than financial results or regulatory filings. There is no indication of financial statements, audit information, or detailed management discussion of financial results. The document is a corporate announcement about a strategic partnership and business development initiative. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it relates to partnership formation and potential capital structure implications through a new entity and financing activities mentioned in the MoU.
2024-04-07 English
Webinar to discuss SYNthesis BioVentures partnership 2 pages 199.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated Monday 8 April 2024 from AdAlta Limited. It announces a webinar hosted by the CEO to discuss a new partnership under a Memorandum of Understanding and general business progress. The content focuses on the announcement of an event and business updates rather than financial results, regulatory filings, or detailed financial reports. The document length is 4272 characters, which is relatively short and primarily serves as an announcement rather than a detailed report or transcript. There is no indication of financial statements, earnings data, or detailed management discussion. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit into more specific categories like earnings release, investor presentation, or management report.
2024-04-07 English
AdAlta presenting at ASX Gems conference 2 pages 181.5KB
Investor Presentation Classification · 90% confidence The document is an ASX announcement dated 20 March 2024 from AdAlta Limited about the CEO presenting at the ASX Gems Conference on 22 March 2024. It provides event details, registration information, and background about the company and its technology. There are no financial statements, earnings data, or detailed financial analysis included. The document is an announcement of an upcoming investor presentation event rather than the presentation itself or a financial report. The length is 4070 characters, which is relatively short and consistent with an announcement. Therefore, the document fits best as an Investor Presentation announcement (IP) or possibly a Regulatory Filing (RNS). However, since it specifically announces a presentation event for investors, the most appropriate classification is Investor Presentation (IP).
2024-03-19 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.